Canary Speech, a leader in AI-powered voice biomarker technology and NeuroLexIQ, The Brain Injury Authority, have announced a strategic partnership to bring objective, voice-based concussion screening into the earliest moment of a personal injury case: the client’s first intake call.
Mild traumatic brain injuries, or mTBIs, are among the most under-documented injuries in personal injury litigation. Every year, thousands of people walk away from car crashes and falls with concussions that go unseen for weeks or months. Symptoms hide, evidence fades and clients can lose the chance to prove what happened to them. This partnership is designed to change that by giving attorneys and their clients an objective signal from the very start of a case, when it matters most.
The collaboration integrates Canary Speech’s voice analysis directly into NeuroLexIQ’s client intake workflow. During a structured intake conversation, often before any medical exam has taken place, the platform analyses subtle patterns in a person’s speech to generate a Concussion Probability Report. When that report flags a potential injury, it opens the door to qEEG validation, pairing voice-derived signals with FDA-cleared neurodiagnostic data to build a single, litigation-ready record.
That structure gives attorneys an objective marker captured at first contact, rather than relying solely on self-reported symptoms that can fade or become harder to substantiate over time. For clients, that means a faster, less invasive path to understanding whether further evaluation is warranted.
“For the past decade, we’ve done the hard work of turning voice into a clinically meaningful signal,” said Henry O’Connell, CEO of Canary Speech. “In personal injury cases, timing is everything. Partnering with NeuroLexIQ lets us put that signal to work at the exact moment it can do the most good.”
“By adding Canary Speech’s voice analysis to our intake process, we can objectively identify potential brain injuries from the first conversation and route the right cases for qEEG testing before symptoms fade and causation becomes harder to establish,” said Mark Slaughter, Founder and CEO of NeuroLexIQ. “It’s a meaningful step forward for how our industry documents and supports these clients.”
NeuroLexIQ and Canary Speech will begin rolling out the integrated intake process with a pilot programme starting 1 July 2026, giving personal injury attorneys early access to the combined voice-and-EEG workflow.
